...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>感染症学雑誌 >Comparison between HIV-1-infected hemophiliacs and non-hemophiliacs on survival and clinical courses after starting highly active antiretroviral therapy
【24h】

Comparison between HIV-1-infected hemophiliacs and non-hemophiliacs on survival and clinical courses after starting highly active antiretroviral therapy

机译：高活度抗逆转录病毒治疗后HIV-1感染血友病和非血友病药与临床疗程的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In order to investigate the long-term prognosis and clinical efficacy of highly active antiretroviral therapy (HAART) in HIV-1-infected hemophiliacs, we compared clinical courses of 69 HIV-1-infected hemophiliacs and 29 non-hemophiliacs all of whom were asymptomatic between 1990 and 1993. Changes of CD4 count during 1990 through 2000 in both groups were not significantly different. The time to death due to AIDS in both groups were also not significantly different. The major causes of death not related to AIDS in hemophiliacs were bleeding, liver cirrhosis, and liver cancer. A total of 55 (39 hemophiliacs and 16 non-hemophiliacs) out of 98 patients survived in 1997. Since then, the 28 hemophiliacs and the 12 non-hemophiliacs received HAART. Although the percentage of patients whose viral loads (VL) decreased to below undetectable level (VL < 400 copies/ml) by the initial HAART regimens without saquinavir were not significantly different, continuation of the same regimens in the hemophiliacs were significantly longer than non-hemophiliacs (84 weeks vs. 51 weeks, p < 0.05). From starting HAART to July 2000, 35.7% of the hemophiliacs were changed regimens three times or more. That is higher prevalence comparing with non-hemophiliacs of 16.7%. This study suggests that there might be the patient group who have to been changed HAART regimens frequently in the hemophiliacs.
机译：为了探讨高活性抗逆转录病毒治疗（HAART）在HIV-1感染的血友病患者中的长期预后和临床疗效，我们比较了69名HIV-1感染的血友病患者的临床疗程和29个非血友病的临床课程是无症状的在1990年至1993年期间。在这两个群体中，1990年至2000年的CD4计数的变化并没有显着差异。由于两组艾滋病导致的死亡时间也没有显着差异。与血友病助剂无关的死亡的主要原因是出血，肝硬化和肝癌。 98例患者共有55例（39个血友病和16名非血友病），于1997年幸存下来。从那时起，28个血友病和12名非血友病患者获得了HAART。虽然在没有Saquinavir的初始HAART方案的病毒载量（VL）降低到未检测到的水平（VL <400拷贝/ mL）的患者的百分比没有显着差异，但在血友病药中的相同方案的延续显着长于非 - 非血友病患者（84周与51周，P <0.05）。从启动HAART到2000年7月，35.7％的血友病患者改变了三次以上的方案。与非血友病患者相比，比较较高的流行率为16.7％。本研究表明，可能有患者组必须经常在血友病中改变HAART方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号